A variant near the interleukin-6 gene is associated with fat mass in Caucasian men

International Journal of Obesity

Volumn 34, Issue 6, 2010, Pages 1011-1019

  Andersson, N ^a,b   Strandberg, L ^a   Nilsson, S ^b   Adamovic, S ^a   Karlsson, M K ^c,d   Ljunggren, O ^e   Mellstrom D ^a   Lane, N E ^f   Zmuda, J M ^g   Nielsen, C ^h   Orwoll, E ^h   Lorentzon, M ^a   Ohlsson, C ^a   Jansson, J O ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

IL6; IL6R; Rs10242595; SNP

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADULT; AGED; ARTICLE; BODY FAT; CAUCASIAN; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPRODUCIBILITY; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN;

ABSORPTIOMETRY, PHOTON; ADIPOSITY; ADOLESCENT; AGED; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-6; SWEDEN; YOUNG ADULT;

MUS;

EID: 77953612512     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2010.27     Document Type: Article

References (43)

1. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003; 149: 1-38.
2. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-997.
3. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.
4. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101: 311-320.
5. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008; 88: 1379-1406.
6. Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 2006; 195: 173-183.
7. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
8. Faldt J, Wernstedt I, Fitzgerald SM, Wallenius K, Bergstrom G, Jansson JO. Reduced exercise endurance in interleukin-6-defi-cient mice. Endocrinology 2004; 145: 2680-2686.
9. Chida D, Osaka T, Hashimoto O, Iwakura Y. Combined interleukin-6 and interleukin-1 deficiency causes obesity in young mice. Diabetes 2006; 55: 971-977.
10. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75-79.
11. Chai Z, Gatti S, Toniatti C, Poli V, Bartfai T. Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice. J Exp Med 1996; 183: 311-316.
12. Flores MB, Fernandes MF, Ropelle ER, Faria MC, Ueno M, Velloso LA et al. Exercise improves insulin and leptin sensitivity in hypothalamus of Wistar rats. Diabetes 2006; 55: 2554-2561.
13. Rothwell NJ, Busbridge NJ, Lefeuvre RA, Hardwick AJ, Gauldie J, Hopkins SJ. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can J Physiol Pharmacol 1991; 69: 1465-1469.
14. Stenlof K, Wernstedt I, Fjallman T, Wallenius V, Wallenius K, Jansson JO. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab 2003; 88: 4379-4383.
15. Benrick A, Schele E, Pinnock SB, Wernstedt-Asterholm I, Dickson SL, Karlsson-Lindahl L et al. Interleukin-6 gene knockout influences energy balance regulating peptides in the hypothalamic paraventricular and supraoptic nuclei. J Neuroendocrinol 2009; 21: 620-628.
16. Li G, Klein RL, Matheny M, King MA, Meyer EM, Scarpace PJ. Induction of uncoupling protein 1 by central interleukin-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue and underlies one mechanism of body weight reduction in rats. Neuroscience 2002; 115: 879-889.
17. Wernstedt I, Edgley A, Berndtsson A, Faldt J, Bergstrom G, Wallenius V et al. Reduced stress-and cold-induced increase in energy expenditure in interleukin-6-deficient mice. Am J Physiol Regul Integr Comp Physiol 2006; 291: R551-R557.
18. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
19. Grallert H, Huth C, Kolz M, Meisinger C, Herder C, Strassburger K et al. IL-6 promoter polymorphisms and quantitative traits related to the metabolic syndrome in KORA S4. Exp Gerontol 2006; 41: 737-745.
20. Huth C, Illig T, Herder C, Gieger C, Grallert H, Vollmert C et al. Joint analysis of individual participants' data from 17 studies on the association of the IL6 variant-174G>C with circulating glucose levels, interleukin-6 levels, and body mass index. Ann Med 2009; 41: 128-138.
21. Qi L, Zhang C, van Dam RM, Hu FB. Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals. J Clin Endocrinol Metab 2007; 92: 3618-3625.
22. Strandberg L, Mellstrom D, Ljunggren O, Grundberg E, Karlsson MK, Holmberg AH et al. IL6 and IL1B polymorphisms are associated with fat mass in older men: the MrOS Study Sweden. Obesity (Silver Spring) 2008; 16: 710-713.
23. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G et al. Replicating genotype-phenotype associations. Nature 2007; 447: 655-660.
24. Wolford JK, Gruber JD, Ossowski VM, Vozarova B, Antonio Tataranni P, Bogardus C et al. A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab 2003; 78: 136-144.
25. Wang H, Zhang Z, Chu W, Hale T, Cooper JJ, Elbein SC. Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. J Clin Endocrinol Metab 2005; 90: 1123-1129.
26. Hamid YH, Urhammer SA, Jensen DP, Glumer C, Borch-Johnsen K, Jorgensen T et al. Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whites. Diabetes 2004; 53: 3342-3345.
27. Esteve E, Villuendas G, Mallolas J, Vendrell J, Lopez-Bermejo A, Rodriguez M et al. Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clin Endocrinol (Oxf) 2006; 65: 88-91.
28. Qi L, Rifai N, Hu FB. Interleukin-6 receptor gene, plasma C-reactive protein, and diabetes risk in women. Diabetes 2009; 58: 275-278.
29. Prentice AM, Jebb SA. Beyond body mass index. Obes Rev 2001; 2: 141-147.
30. Lorentzon M, Swanson C, Andersson N, Mellstrom D, Ohlsson C. Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J Bone Miner Res 2005; 20: 1334-1341.
31. Lorentzon M, Mellstrom D, Ohlsson C. Age of attainment of peak bone mass is site specific in Swedish menFthe GOOD study. J Bone Miner Res 2005; 20: 1223-1227.
32. Mellstrom D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, Mallmin H et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006; 21: 529-535.
33. Blank JB, Cawthon PM, Carrion-Petersen ML, Harper L, Johnson JP, Mitson E et al. Overview of recruitment for the Osteoporotic Fractures in Men Study (MrOS). Contemp Clin Trials 2005; 26: 557-568.
34. Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K et al. Design and baseline characteristics of the Osteoporotic Fractures in Men (MrOS) StudyFa large observational study of the determinants of fracture in older men. Contemp Clin Trials 2005; 26: 569-585.
35. Fan JB, Oliphant A, Shen R, Kermani BG, Garcia F, Gunderson KL et al. Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 2003; 68: 69-78.
36. Andersson N, Strandberg L, Nilsson S, Ljungren O, Karlsson MK, Mellstrom D et al. Variants of the interleukin-1 receptor antagonist gene are associated with fat mass in men. Int J Obes (London) 2009; 33: 525-533.
37. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
38. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
39. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003; 289: 1826-1832.
40. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
41. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hyper-cytokinemia. J Clin Endocrinol Metab 2000; 85: 1151-1158.
42. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund Pedersen B. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 2000; 529 (Part 1): 237-242.
43. Glund S, Krook A. Role of interleukin-6 signalling in glucose and lipid metabolism. Acta Physiol (Oxf) 2008; 192: 37-48.